AD
About
Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 5 investors are based in Lebanon, New Hampshire, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- Lebanon, US
Contact Information
linkedin.com/in/••••••••
Find more investors like Adimab
Search Investors